What the product information says
We searched the US labels, EU product information and Canadian monographs for polyuria, pollakiuria, nocturia and frequent urination. None lists them as a reaction. The urinary entries that do appear concern infections, and the kidney warning concerns fluid loss rather than extra urine.
| Document and population | Entry | Medicine | Comparison |
|---|---|---|---|
| Saxenda®, US label, adults [2] | Urinary tract infection | 4.3% | Placebo 3.1% |
| Wegovy®, US label, adolescents 12 and older [1] | Urinary tract infection | 4% | Placebo 2% |
| Trulicity®, Canadian monograph, placebo-controlled pool [5] | Urinary tract infection | 3.8% (0.75 mg), 4.2% (1.5 mg) | Placebo 3.7% |
| Liraglutide, MedlinePlus drug page [6] | Difficulty urinating, or pain or burning on urination | Listed, no rate | — |
| Zepbound® and Wegovy®, US labels [1][3] | Acute kidney injury after fluid loss | Postmarketing reports, no rate | — |
| Mounjaro®, EU product information [4] | Frequent urination | Not listed | — |
What studies have measured
The most direct evidence comes from 24-hour urine collections, which measure total volume along with the minerals that affect kidney stones. A study of Medicare beneficiaries with kidney stones compared 349 people with a recent GLP-1 prescription with matched controls, and followed 154 of them before and after starting. GLP-1 medicines were not linked to any significant change in urine parameters, including volume. SGLT-2 inhibitors, a different diabetes class, were linked to a higher urine volume [9].
A smaller study of 44 people with kidney stones who lost weight on GLP-1 based medicines over about a year also found no meaningful change in total urine volume [10]. Both studies are observational and involved people with a history of stones, so they may not represent everyone.
Laboratory studies give a mechanism that could, in theory, increase urine. A review of controlled human experiments found that natural GLP-1 makes the kidneys excrete more sodium, but only when the body is already loaded with fluid, and those experiments lasted hours, not months [8]. The Canadian Wegovy® monograph also notes a brief increase in urine output in rats [11]. Neither finding has been shown to cause frequent urination in people using these medicines.
Why you might still be going more often
- Drinking more on purpose. Many care teams and labels stress fluids to avoid dehydration when nausea, vomiting or diarrhea occur [1][3]. More fluid in usually means more urine out.
- A second diabetes medicine. If your plan also includes an SGLT-2 inhibitor, that class increases urine volume, as the Medicare study measured [9].
- High blood sugar. Diabetes that is not well controlled causes frequent urination, often with thirst and tiredness [12].
- An infection. Urinary tract infection is a common cause of frequency and urgency [12], and appears in some GLP-1 tables at rates slightly above placebo [1][2][5].
- Caffeine and alcohol, both named by MedlinePlus as causes [12].
Other causes of frequent urination
MedlinePlus lists common causes as urinary tract infection, an enlarged prostate in middle-aged and older men, inflammation of the urethra, vaginitis, nerve problems and caffeine. Less common causes include alcohol, anxiety, pregnancy, interstitial cystitis, overactive bladder, diuretic medicines, stroke and, rarely, bladder cancer or a pelvic tumour [12].
Weight loss itself may help some bladder symptoms. A 2026 urology review concluded that GLP-1 medicines may benefit stress incontinence and overactive bladder indirectly, through weight loss, while noting that controlled trials with urinary endpoints are lacking [13].
The direction that matters more: less urine
The kidney warning in GLP-1 labels is about dehydration. Postmarketing reports describe acute kidney injury, sometimes needing dialysis, mostly in people who had nausea, vomiting or diarrhea leading to fluid loss. The labels ask prescribers to monitor kidney function in people with such reactions, especially when starting or increasing the dose [1][3].
For patients, MedlinePlus lists decreased urination, or swelling of the legs, ankles or feet, among the semaglutide and liraglutide side effects that need a doctor straight away [6][7]. Dark urine and passing very little after a day of vomiting deserve more attention than an extra trip to the bathroom.
What may help
MedlinePlus suggests a voiding diary: write down the times you pass urine and roughly how much, and take it to your appointment [12]. For night-time trips, it suggests not drinking large amounts before bed and cutting back on caffeine and alcohol [12].
Do not cut back sharply on fluids to avoid bathroom trips while stomach side effects are active, because the labels link fluid loss to kidney injury [1][3]. If you are unsure how much to drink, ask your prescriber, particularly if you have kidney or heart disease.
Wegovy® and Saxenda® are registered trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound® and Trulicity® are registered trademarks of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Novo Nordisk or Eli Lilly and Company.
When to get help
The signs and contact information below come from this article’s sourced guidance.
Today
- Frequent urination with fever, back or side pain, vomiting or shaking chills
Contact: Your clinician, right away
MedlinePlus [12]
- Frequent urination with more thirst or appetite, tiredness or sudden weight loss
Contact: Your clinician, right away
MedlinePlus [12]
- Passing much less urine than usual, or swelling of legs, ankles or feet
Contact: Your prescriber, right away
- Ongoing vomiting or diarrhea with little fluid kept down
Contact: Your prescriber
- Bloody or cloudy urine, pain or burning when passing urine
Contact: Your clinician
At your next appointment
- Frequency or urgency without drinking more, or that changes daily life
Contact: Your prescriber or primary care clinician
MedlinePlus [12]